PANZYGA (normal human immunoglobulin) - Immunoglobulin

Opinions on drugs - Posted on Jul 10 2025

Reason for request

Inclusion on list

Summary of opinion

Favourable opinion for reimbursement in the MA indications.

No clinical added value in the care pathway.

Clinical Benefit

Substantial

The clinical benefit of PANZYGA (normal human immunoglobulin) 100 mg/mL is high in measles pre- and post-exposure prophylaxis for susceptible adults, children and adolescents (0 to 18 years) in whom active immunisation is contraindicated or not recommended.

Clinical Added Value

no clinical added value

PANZYGA (normal human immunoglobulin) 100 mg/mL provides no clinical added value (CAV V) compared to the other normal human immunoglobulins administered intravenously or subcutaneously already listed.